American Merck acquires Cidara Therapeutics for $9.2 billion

2152
2
AK&M 22 November 2026 04:42

Merck&Co. (MSD outside the United States and Canada) has entered into an agreement to acquire Cidara Therapeutics Inc. for $9.2 billion. This is reported in a press release from Merck.

The financing of the transaction provides for the payment of $221.5 (twice the closing price on November 12, 2025), reflecting the strategic value of CD388's core asset, which is undergoing the third phase of ANCHOR trials and has received approval from the US regulator for use as a breakthrough therapy and accelerated treatment. CD388 is a long-acting drug for the prevention of influenza A and B. in high-risk groups, including the elderly and people with weakened immune systems.

The deal is aimed at strengthening Merck's position in the development of antiviral drugs for the treatment of respiratory diseases as compensation for the upcoming expiration of patents, including the anti-cancer drug Keytruda. The loss of patents will reduce sales by $18 billion in 2028.

The transaction is expected to be completed in the first quarter of 2026 after regulatory approval. BofA Securities Inc. and Gibson Dunn LLP act as advisors to Merck, while Evercore and Goldman Sachs&Co. — Cidara consultants.

In addition, in July 2025, Merck acquired the manufacturer of respiratory drugs Verona Pharma Plc for $10 billion, winning a tender from pharmaceutical companies amid competition for new drugs to increase the range of drugs.

In 2025, the value of biotech and pharmaceutical deals increased by 31% to $187 billion, including the acquisition of Intra-Cellular Therapies Inc by Johnson & Johnson for $14 billion and the acquisition of Avidity Biosciences Inc. by Novartis AG. Pfizer Inc. has won the bidding from Novo Nordisk A/S for biotech company Metsera Inc., concluding a deal worth $10 billion.

Merck&Co. (MSD outside the United States and Canada) is a multinational biopharmaceutical company headquartered in Kenilworth, New Jersey. MSD manufactures medicines and vaccines for the prevention and treatment of the most complex diseases (oncology, hepatitis C, infectious diseases, including HIV infection and Ebola). MSD Animal Health offers veterinary medicines for pets, while MSD Animal Health offers a wide range of digital tools for monitoring and managing animal health.

Cidara Therapeutics, Inc. is an American biotech company developing targeted therapies for the treatment of cancer and other serious diseases. The company is also developing the Cloudbreak platform, which allows the development of new drug conjugates with Fc, including CD388. The company is headquartered in San Diego, California.

Read also in our Telegram channel "Mergers and acquisitions. AK&M».